Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Receivables - Other data on file, last reported at $300000.0 in Q1 2026.

• Receivables - Other for Q1 2026 came in at $300000.0, down 80.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $300000.0 (down 80.84% YoY), and the FY2025 annual result was $194000.0, changed N/A from the prior year.
• Receivables - Other improved to $300000.0 in Q1 2026 per AKBA's latest filing, from $194000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $56.6 million in Q2 2022 and troughed at $194000.0 in Q4 2025.
• A 5-year average of $5.8 million and a median of $1.8 million in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 2837.03% in 2022, then sank 99.07% in 2023.
• A 5-year view of Receivables - Other shows it stood at $781000.0 in 2022, then soared by 326.76% to $3.3 million in 2023, then sank by 45.24% to $1.8 million in 2024, then slumped by 89.37% to $194000.0 in 2025, then soared by 54.64% to $300000.0 in 2026.
• Business Quant data shows AKBA's Receivables - Other at $300000.0 in Q1 2026, $194000.0 in Q4 2025, and $5.4 million in Q2 2025.